The FDA granted breakthrough therapy designation to colistimethate sodium powder for nebulization solution to reduce pulmonary exacerbations in adults with non-cystic fibrosis bronchiectasis and Pseudomonas aeruginosa.
Colistimethate sodium powder for nebulization solution (CMS I-neb, Zambon) is being developed as a potential first-in-class inhaled therapy for adults with non-cystic fibrosis bronchiectasis colonized with P. aeruginosa. CMS I-neb delivers targeted drug concentrations directly to the disease site to minimize systemic exposure that can cause toxicity and adverse events, according
Inhaled therapy receives FDA breakthrough designation for non-cystic fibrosis bronchiectasis
The FDA granted breakthrough therapy designation to colistimethate sodium powder for nebulization solution to reduce pulmonary exacerbations in adults with non-cystic fibrosis bronchiectasis and Pseudomonas aeruginosa.
Colistimethate sodium powder for nebulization solution (CMS I-neb, Zambon) is being developed as a potential first-in-class inhaled therapy for adults with non-cystic fibrosis bronchiectasis colonized with P. aeruginosa. CMS I-neb delivers targeted drug concentrations directly to the disease site to minimize systemic exposure that can cause toxicity and adverse events, according